Literature DB >> 18375325

A preliminary study of a new tranexamic acid dosing schedule for cardiac surgery.

Gregory A Nuttall1, Maria Cristina Gutierrez, Jonathan D Dewey, Michael E Johnson, Lance J Oyen, Andrew C Hanson, William C Oliver.   

Abstract

OBJECTIVE(S): The authors have developed an alternative dosing schedule for tranexamic acid that incorporates the effects of renal function on tranexamic acid concentrations. The objectives of this study were to determine if this new dosing schedule can achieve the desired plasma concentration of tranexamic acid and reduce intra- and interpatient variability in tranexamic acid plasma concentrations relative to the current dosing schedule.
DESIGN: A prospective randomized trial.
SETTING: A tertiary referral medical center hospital. PARTICIPANTS: Cardiac surgery patients.
INTERVENTIONS: Cardiac surgery patients were randomly assigned to receive the authors' standard tranexamic acid loading dosage of 10 mg/kg given over 20 minutes, followed by an infusion of 1 mg/kg/h (9 patients), or the new drug dosage schedule described later (11 patients).
MEASUREMENTS AND MAIN RESULTS: Perioperative plasma tranexamic acid concentrations were measured using high-performance liquid chromatography. From repeated-measures analysis of variance, a significant (p < 0.001) time-by-treatment interaction effect was detected indicating that differences in mean tranexamic acid concentration between treatment groups were dependent on time period. Among patients receiving the standard dosing regimen, those with renal insufficiency had lower tranexamic acid concentration at 5 minutes on cardiopulmonary bypass (p = 0.003). For patients receiving the experimental regimen, the mean tranexamic acid concentration did not differ significantly at any time point between patients with and without renal insufficiency (p > 0.20 at all time points).
CONCLUSIONS: The new dosing protocol for tranexamic acid resulted in more consistent blood concentrations of tranexamic acid, but not stable tranexamic acid levels >20 microg/mL on cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18375325     DOI: 10.1053/j.jvca.2007.12.016

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  5 in total

1.  Temporally and regionally disparate differences in plasmin activity by tranexamic acid.

Authors:  Daryl L Reust; Scott T Reeves; James H Abernathy; Jennifer A Dixon; William F Gaillard; Rupak Mukherjee; Christine N Koval; Robert E Stroud; Francis G Spinale
Journal:  Anesth Analg       Date:  2010-03-01       Impact factor: 5.108

2.  Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial.

Authors:  Jia Shi; Chenghui Zhou; Wei Pan; Hansong Sun; Sheng Liu; Wei Feng; Weijian Wang; Zhaoyun Cheng; Yang Wang; Zhe Zheng
Journal:  JAMA       Date:  2022-07-26       Impact factor: 157.335

3.  A comparison of high-dose and low-dose tranexamic acid antifibrinolytic protocols for primary coronary artery bypass surgery.

Authors:  Stephen M McHugh; Lavinia Kolarczyk; Robert S Lang; Lawrence M Wei; Marquez Jose; Kathirvel Subramaniam
Journal:  Indian J Anaesth       Date:  2016-02

4.  Giving tranexamic acid to reduce surgical bleeding in sub-Saharan Africa: an economic evaluation.

Authors:  Carla Guerriero; John Cairns; Sudha Jayaraman; Ian Roberts; Pablo Perel; Haleema Shakur
Journal:  Cost Eff Resour Alloc       Date:  2010-02-17

5.  Rotational thromboelastometry and conventional coagulation tests in patients undergoing major cardiac or aortic surgery: a retrospective single-center cohort study.

Authors:  Cornelius Keyl; Albina Bashota; Friedhelm Beyersdorf; Dietmar Trenk
Journal:  J Thromb Thrombolysis       Date:  2021-07-07       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.